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httpcense.Abstract Background: Gram-negative (G-ve) bacilli, particularly Pseudomonas aeruginosa and
Acinetobacter baumannii, are important opportunistic multidrug-resistant (MDR) pathogens in hos-
pitalized patients, contributing to their morbidity and mortality. These organisms may still keep
their sensitivity to colistin and allowed its use for these selective therapeutic indications.
Objectives: The aim of the present study is to evaluate and compare the effectiveness and safety
of both combined intravenous (i.v.) colistin with aerosolized colistin versus i.v. colistin alone in nos-
ocomial pneumonia due to MDR G-ve pathogens in critically ill patients.
Methods: 40 Patients were hospitalized in ICU due to different etiologies. These patients expe-
rienced nosocomial pneumonia. The pathogenic organisms were G-ve MDR bacilli and only sus-
ceptible to colistin. The ﬁrst group received both i.v. colistin with aerosolized colistin versus (vs.)
the second group who received i.v. colistin alone.
Results: Mortality was less in patients who received i.v. plus inhaled colistin.
Conclusion: Colistin is a reasonable safe last-line therapeutic alternative for pneumonia due to
MDR G-ve pathogens. Aerosolized colistin may be considered as a useful adjunctive to i.v. colistin.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.6501943.
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According to data from the Centre for Disease Control and
prevention (CDC) and the Nosocomial Infection Surveillance
System (NISS), G-ve bacilli are the most common causative
organisms for nosocomial pneumonia. Pseudomonas aerugin-
osa and Acinetobacter baumannii are the most serious etiolo-
gies for nosocomial pneumonia, and more importantly the
most common multidrug-resistant (MDR) G-ve pathogens inhe Egyptian Society of Chest Diseases and Tuberculosis.
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448 M. Amin et al.these patients [1]. The increased prevalence of MDR in multi-
ple parts of the world and lack of development of new antibi-
otics to ﬁght MDR G-ve have created a new antibiotic
therapeutic failure, leading to the use and renewed interest of
the previously neglected class of polymyxins [2]. Until recently,
the polymyxin class was mainly used via inhalation to treat
high-density respiratory tract colonization due to MDR P.
aeruginosa in patients with cystic ﬁbrosis since this class was
thought to be unacceptably toxic when administered parenter-
ally. However, in recent years, colistin (polymyxin E) was ob-
served to be less toxic than previously proposed, and to offer
an acceptable efﬁcacy for treatment of severe infections due
to MDR G-ve bacteria [3]. Colistin is now being used increas-
ingly as a last treatment option for treatment of nosocomial
pneumonia with MDR G-ve bacteria [2].
Colistin belongs to polymyxins which were isolated for the
1st time from Bacillus Colistinum in 1949 [4,5]. Polymyxins are
a group of polypeptide antibiotics which includes ﬁve different
chemical compounds (polymyxins A, B, C, D, and E). Only
two of them, polymyxins B and E, have been used in clinical
practice. Colistin binds to the gram-negative bacterial cell
membrane, which leads to its increase in permeability changes
and ultimately cell death [4]. Most G-ve microorganisms are
susceptible to colistin, including multidrug-resistant A. bau-
mannii and P. aeruginosa, Klebsiella pneumonia and Escherichia
coli strains. However Proteus species, Neisseria species, Serra-
tia species, and Providencia species, as well as anaerobic bacte-
ria, are resistant to colistin [6].
Early clinical experience with colistin showed a high inci-
dence of toxicity, namely, nephrotoxicity (acute renal failure),
neurotoxicity (facial paresis, dizziness, muscle weakness, ver-
tigo, confusion, neuromuscular blockade and apnea), some-
times with fatal consequences [7–9].
2. Aim of the present study
The aim of the present study is to report and evaluate 2 years
experience with the use of colistin and compare the role of
combined i.v. colistin and inhaled colistin vs. i.v. colistin alone
for treatment of nosocomial pneumonia due to MDR G-ve ba-
cilli in critically ill patients.
3. Patients and methods
This prospective study enrolled patients in ICUs of 300 beds of
3 tertiary specialized hospitals (burns and plastic surgery hos-
pital, orthopedic hospital and organ transplantation center)
fromMay 2011 till August 2012. 40 patients were prospectively
followed in this study who suffered from ICU-AP or VAP. The
isolated pathogens were MDR G-ve bacilli and were only sen-
sitive to colistin. The primary objective was to compare the
treatment outcomes of the pneumonia between different colis-
tin treatment groups (combined parenterally with inhaled
colistin therapy ‘‘28 patients’’ or only parental i.v. colistin
‘‘12 patients’’).
All individuals were subjected to the following procedures:
 Thorough medical history and full clinical
examination.
 Full data about their age, sex, and smoking status.
 Radiological examinations. Routine lab investigations e.g. CBC, ESR, liver and
kidney function tests; urinalysis, glucose proﬁle.
 Acute Physiology and Chronic Health Evaluation
(APACH II) was scored on admission to the ICU. This
score was used as a predictor of hospital mortality risk.
 Administration of i.v. colistin (colistimethate sodium):
all patients enrolled in the study had received i.v. colis-
tin as a dose of 1–2 million IU every 6–8 h (62500 IU/
kg/day) according to body weight with normal renal
function. Treatment continued for 12–15 days with
close monitoring for the possibility of nephrotoxicity
and neurotoxicity [10].
 Administration of inhaled colistin: in patients under
mechanical ventilation (MV), 2 million IU colistin was
diluted in 2 mL sterile normal saline 0.9% and delivered
via the ventilator every 12 h. In spontaneously breath-
ing patients, 2 million IU of colistin was diluted in
4 mL of normal saline and nebulized with 8 L/min oxy-
gen ﬂow. Treatment continued for 12–15 days [10].
 Microbiological testing: identiﬁcation of all causative
pathogens was performed using routine microbiologi-
cal methods. Susceptibility testing was performed by
the disk diffusion method to commonly used antibiot-
ics; namely, penicillins (piperacillin/tazobactam) and
amoxicillin/clavulanate), cephalosporins (cefepime,
cefotriaxone, ceftazidime), carbapenems (meropenem),
quinolones (ciproﬂoxacin, levoﬂoxacin), aminoglyco-
sides (amikacin, gentamicin) and colistin. Susceptibility
to colistin was determined by the use of the colistin
Etest strip. Results were interpreted as showing suscep-
tibility of a bacterial isolate to colistin when the respec-
tive minimum inhibitory concentration was 2 mg/mL.
All patients were sensitive to colistin [11].
 Pneumonia deﬁnition:Diagnosis of pneumonia ‘‘accord-
ing to the criteria of the American Thoracic Society [12]
was based on radiological (new or progressive and per-
sistent inﬁltrate), clinical (fever > 38Co, purulent respi-
ratory secretions) and laboratory ﬁndings (abnormal
white blood cell count < 4000/ll ‘‘leukopenia’’
OR > 12000/ll ‘‘leukocytosis’’ and worsening gas
exchange) [13]. All patients should have microbiologi-
cally documented pneumonia based on quantitative cul-
tures of bronchial sections [14,15]. Microbiological
criteria required a quantitative threshold of 106 cfu/ml
from tracheal aspirate, and >104 cfu/ml for broncho-
scopic bronchoalveolar lavage (BAL). Reliable induced
purulent sputum sample is deﬁned as secretions from
lower respiratory tract that contain >25 neutrophils
and <10 squamous epithelial cells per low power ﬁeld
(100·) with or without alveolar macrophages [16].
 ICU-AP and VAP deﬁnitions: pneumonia occurring at
least 48 h after ICU admission or initiation of mechan-
ical ventilation respectively [11].
 MDR deﬁnition: non-susceptibility to at least six of the
following antibiotics: meropenem, amikacin, piperacil-
lin–tazobactam, ceftazidime, cefepime, aztereonam and
ciproﬂoxacin [17].
 Outcome deﬁnitions: (1) Cure deﬁned as resolution of
presenting symptoms and signs of the infection by the
end of colistin treatment. (2)Failed was deﬁned as per-
sistence or worsening of presenting symptoms and/or
signs of the infection during colistin administration.
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4. Results
4.1. Identiﬁed cases
We identiﬁed 40 patients who received i.v. colistin for a micro-
biologically documented MDR G-ve pneumonia. This study
was preformed during the period May 2010 to August 2012.
28 patients received both i.v. plus inhaled colistin, whereas
12 patients received i.v. colistin alone.4.2. Outcomes
Table 1 shows the demographic and clinical features of the
studied patients and their outcomes. The bivariable analyses
showed that blood transfusion and the duration of administra-
tion of i.v. colistin were differently distributed between the two
groups of patients. The outcome of infection was cure for 22/
28 patients (78%) who received combined i.v. plus inhaled
colistin vs. 7/12 patients (58.3%) who received i.v. colistin
alone (p< 0.05). The use of inhaled colistin was the only inde-
pendent variable signiﬁcantly associated with the cure of nos-
ocomial pneumonia in the multivariable analysis (OR 3.49,
93% CI 2.0–4.90). Mortality was 8/28 (28%) in patients whoTable 1 Comparison of demographic and clinical characteristics, inc
combination with inhaled colistin vs. colistin i.v. monotherapy.
C
Demographic
Age, years (mean ± SD) 5
Sex (male) n/N (%) 1
Apache II score (mean ± SD) 1
Co morbidity n/N (%)
Cardiovascular 1
Pulmonary 6
DM 9
Hepatic injury 2
Hematological 3
Neurological 6
Previous hospitalization n/N (%) 6
Previous antibiotic use n/N (%) 9
Duration of hospitalization until the1st day of colistin (mean ± SD) 1
Duration of ICU stay till 1st day of colistin, (mean ± SD) 9
Duration of MV till the 1st day of colistin 7
Special treatment n/N (%)
Blood transfusion 1
L-thyroxin 3
Urinary catheter n/N (%) 2
Tracheostomy n/N (%) 1
Bronchoscopy n/N (%) 6
i.v. colistin, days (mean ± SD) 1
Dosage of i.v. colistin, IU (mean ± SD) 9
Responsible pathogens, n/N (%)
Acinetobacter baumannii 1
Pseudomonas aeruginosa 7
Klebsiella pneumonia 3
Outcomes; n/N (%)
Cure 2
Mortality 8received i.v. plus inhaled colistin vs. 5/12 (41%) patients who
received i.v. colistin alone (p< 0.05).
The toxicity of colistin was assessed in the present study.
However, no serious adverse events of inhaled colistin (such
as disturbed renal function, neurological abnormalities, bron-
choconstriction chest pains) were recorded.
Table 2 shows the demographic and clinical features of the
patients who died compared to those who survived. The
bivariable analysis showed that older age, greater APACHE
II score, and a lower daily dosage of i.v. colistin were associ-
ated with higher mortality. These variables, along with the
type of colistin treatment (i.v. plus inhaled vs. i.v. alone), were
entered into a multivariable analysis. A higher APACHE II
score (OR 2.1, 95% CI 0.89–1.03), and a lower daily dosage
of i.v. colistin (OR per million IU 0.79, 95% CI 0.59–0.89) re-
mained statistically signiﬁcant predictors of mortality in this
model.
Also tracheostomy and bronchoscopy procedures were sig-
niﬁcantly more in the died group. However this may be due to
the severity of disease, long duration of MV and poor response
to the administered antibiotics.
5. Discussion
The present study demonstrated that the infection outcome of
VAP caused by MDR strains of G-ve pathogens was better inluding outcomes, of patients with VAP treated with colistin i.v. in
olistin i.v. and inhaled (n= 28) Colistin i.v. (n= 12) p Value
5.6 ± 21.9 60.5 ± 4.5 >0.05
5/28 (54%) 7/12 (58%) >0.05
8.1 ± 5 19.1 ± 7 >0.05
1/28(40%) 5/12(39) >0.05
/28(20%) 3/12(22%) >0.05
/28 (30%) 4/12 (29%) >0.05
/28 (5%) 1/12 (8%) >0.05
/28 (8%) 1/12(8%) >0.05
/28(20%) 3/12(18%) >0.05
/28(20%) 3/12 (18%) >0.05
/28 (30%) 4/12 (33%) >0.05
5.3 ± 9.5 13.5 ± 7.5 >0.05
.8 ± 4.5 11.5 ± 3.8 >0.05
.6 ± 4.3 8.1 ± 6.1 >0.05
6/28 (60%) 10/12 (80%) <0.05
/28 (10%) 2/12(16%) >0.05
8/28(100%) 12/12(100%) >0.05
4/28(50%) 7/12(58%) >0.05
/28(20%) 2/12 (18%) >0.05
5.3 ± 8.7 14.1 ± 9.4 <0.05
.2 ± 16 8.4 ± 20 >0.05
8/28 (65%) 8/12 (70%) >0.05
/28 (25%) 3/12 (25%) >0.05
/28 (10%) 1/12 (12%) >0.05
2/28 (78%) 7/12 (60%) <0.05
/28 (28%) 5/12 (41%) <0.05
Table 2 Predictors of mortality (univariate analysis).
Died 16/40 Survived 24/40 p Value
Demographic
Age, y (mean ± SD) 70.4 ± 9.7 50.9 ± 12.7 <0.05
Sex (male), n/N(%) 9/16 (56%) 13/22 (59%) >0.05
APACH II score (mean ± SD) 21.3 ± 7.2 15.3 ± 7 <0.05
Comorbidity, n/N (%)
Cardiovascular 7/16 (41%) 9/24 (37%) >0.05
Pulmonary 4/16 (25%) 5/24 (20%) >0.05
DM 5/16 (31%) 7/24 (29%) >0.05
Hepatic injury 1/16(6%) 2/24 (8%) >0.05
Hematological 1/16 (6%) 3/24 (12%) >0.05
Neurological 4/16 (25%) 5/24 (20%) >0.05
Previous hospitalization n/N (%) 4/16 (25%) 5/24 (20%) >0.05
Previous antibiotic use n/N (%) 5/16 (31%) 7/24 (29%) >0.05
Duration of hospitalization until the 1st day of colistin (mean ± SD) 16.4 ± 9.8 17.1 ± 7.5 >0.05
Duration of ICU stay till 1st day of colistin, (mean ± SD) 7.9 ± 3.2 8.1 ± 1.2 >0.05
Duration of MV till the 1st day of colistin 6.2 ± 5.1 7.2 ± 5.1 >0.05
Special treatment n/N (%)
Blood transfusion 10/16 (63%) 16/24 (66%) >0.05
L-thyroxin 2/16(12%) 3/24 (12%) >0.05
Urinary catheter n/N (%) 16/16(100%) 24/24(100%) NA
Tracheostomy n/N (%) 14/16 (87%) 7/24 (29%) <0.05
Bronchoscopy n/N (%) 6/16(37%) 2/24(8%) <0.05
i.v. colistin, days (mean ± SD) 13.9 ± 9.9 18.1 ± 10.2 >0.05
Dosage of i.v. colistin, IU (mean ± SD) (5.4 ± 3.5) · 106 (7.9 ± 1.9) · 106 <0.05
Responsible pathogens, n/N (%)
Acinetobacter baumannii 9/16 (75%) 17/24 (70%) >0.05
Pseudomonas aeruginosa 5/16 (30%) 5/24 (20%) >0.05
Klebsiella pneumonia 2/16 (12%) 2/24 (8%) >0.05
Outcomes; n/N (%)
Colistin use (i.v. pulse inhaled) 8/16 (50%) 20/24 (83%) <0.05
Colistin use (i.v. alone) 8/16 (50%) 4/24 (16%) <0.05
450 M. Amin et al.patients who received combined inhaled colistin along with i.v.
colistin vs. i.v. colistin alone. The use of inhaled colistin was an
independent predictor of cure of VAP. Mortality was signiﬁ-
cantly less in patients who received combined inhaled colistin
with i.v. colistin [18]. It has been assumed that the delivery
of antimicrobial directly to the site of infection is clinically
beneﬁcial by increasing topical drug levels [19,20]. Inhaled
antibiotics such as tobramycin, amikacin and colistin have
mainly been used to treat patients with cystic ﬁbrosis with gen-
erally favorable results [21,22]. In the present study, patients in
the i.v. plus inhaled colistin group received i.v. colistin for a
longer period of time than patients in the i.v. colistin alone
group (Table 1). Because more patients in the i.v. plus inhaled
colistin group showed clinical improvement, these patients re-
ceived the full course of treatment for VAP caused by G-ve
pathogens, which is approximately 2–3 weeks [23].
The present study demonstrated statistically signiﬁcant dif-
ference in ICU mortality between patients who received in-
haled plus i.v. colistin and those who received i.v. colistin
alone which was less in the former group [24]. APACHE II
score was predictor of mortality in the study. Colistin is recom-
mended in the latest guidelines of the American Thoracic Soci-
ety as a last therapeutic resort for the treatment of VAP and is
usually administered in patients with the most severe clinical
condition [25]. Some studies have shown that the administra-
tion of inhaled colistin should not be accompanied with a de-
crease in the dosage of i.v. administered colistin, which may be
performed to prevent dose-related toxicity, particularly neph-
rotoxicity [26]. Similarly, in the present cohort of patients, alower i.v. colistin daily dosage was independently related to
higher mortality.
The present study has some limitations. Inhaled colistin was
usually administered via conventional nebulizers, which do not
control the particle size, and therefore the actual amount of the
drug delivered to the lungs could not be accurately estimated
[27,28].6. Conclusion
Colistin is a reasonable safe last-line therapeutic alternative for
pneumonia due to MDR G-ve pathogens. Aerosolized colistin
may be considered as a useful adjunctive to i.v. colistin in these
patients. However, the severity of these infections in the ICU
setting means that treatment just with aerosolized colistin is
unlikely to be sufﬁcient. This is in contrast to therapeutic strat-
egies employed in patients with cystic ﬁbrosis, in which initial
lung colonization with P. aeruginosa strains is commonly trea-
ted with aerosolized colistin alone. Randomized controlled tri-
als studying the possible additional beneﬁts and risks
associated with use of nebulized colistin, as an adjunct to intra-
venous antimicrobial treatment are needed.References
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